Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practice, the clinical benefit of these agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenger, Justin B., Santos, Napoleon, Liu, Yanxia, Dallas, Jennifer, Subbiah, Sukanthini, Hochwald, Steven, Huang, Emina H., Dang, Duyen T., Allegra, Carmen J., Luesch, Hendrik, Dang, Long H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179415/
https://www.ncbi.nlm.nih.gov/pubmed/21949574
http://dx.doi.org/10.1007/s12156-011-0082-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179415/
https://www.ncbi.nlm.nih.gov/pubmed/21949574
http://dx.doi.org/10.1007/s12156-011-0082-3

Ejemplares similares